Viatris to Acquire Pacira BioSciences for $1.65 Billion in Cash, Building a Non-Opioid Pain Franchise

VTRS agreed on October 8, 2026 to acquire PCRX for $36.50 per share in cash, an aggregate equity value of $1.65 billion, according to the companies' announcement. The price is about a 45% premium to Pacira's Wednesday close of $25.20. The deal adds EXPAREL, for acute postsurgical pain, and ZILRETTA, for osteoarthritis knee pain, which Viatris says are synergistic with its own fast-acting meloxicam and make it a leader in non-opioid pain management. Some headlines rounded the price to $1.7 billion; the announced equity value is $1.65 billion.

Pacira brings real but slow-growing revenue. It generated about $746 million of total revenue and $177 million of adjusted EBITDA in the twelve months to June 30, 2026, per the release, and its two biggest drugs booked $692 million of sales in 2025, up about 4% from 2024. Viatris plans to fund the purchase mainly from excess cash with the remainder from short-term borrowings, and says the deal is expected to be immediately accretive to its financial guidance metrics. Viatris will run a tender offer, and closing requires a majority of Pacira's shares to be tendered plus expiry of the regulatory waiting period.

Pacira stock rose about 44% on the news and closed at $36.39, just under the offer. That pinning explains the analyst moves that followed: Jefferies cut Pacira from Buy to Hold with a $36.00 target, and Oppenheimer moved it to Perform from Outperform. Jefferies analyst Glen Santangelo called the deal positive for Pacira and a more mixed picture for Viatris, flagging generic competition for EXPAREL expected in 2030 and a NO-PAIN reimbursement contract that expires in December 2027.

What to watch: the tender offer launch and the regulatory waiting period, whether any competing bid emerges (none has been reported), and the FDA decision on Viatris's fast-acting meloxicam due December 27, which is the product Viatris expects these assets to complement.